Overview

A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a first in human Phase 1 study to evaluate the safety, tolerability and pharmacokinetics with healthy young and elderly adult male volunteers after receiving single and multiple ascending dose of BEY2153.
Phase:
Phase 1
Details
Lead Sponsor:
BeyondBio Inc.